11.12

0.40% 0.04

Verve Therapeutics Inc (VERV)

Overview News Price History Option Chain Financials Why VERV Down? Discussions Forecast

Verve Therapeutics Inc stock is traded at $11.12, with a volume of 1.31M. It is up +0.40% in the last 24 hours and up +0.13% over the past month. Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.

Previous Close:

$11.08

Open:

$11.11

24h Volume:

1.31M

Relative Volume:

0.29

Market Cap:

$991.27M

Revenue:

$20.65M

Net Income/Loss:

$-192.65M

P/E Ratio:

-4.2934

EPS:

-2.59

Net Cash Flow:

$-134.39M

1W Performance:

+0.95%

1M Performance:

+0.13%

6M Performance:

+39.23%

1Y Performance:

+44.47%

1-Day Range:

$11.08

$11.14

1-Week Range:

$10.90

$11.14

52-Week Range:

$2.8647

$11.40

Verve Therapeutics Inc Stock (VERV) Company Profile

Name

Verve Therapeutics Inc

Sector

Healthcare (1167)

Industry

Biotechnology (653)

Phone

(978) 501-3026

Address

201 BROOKLINE AVENUE, BOSTON

Employee

274

Twitter

Next Earnings Date

Latest SEC Filings

VERV's Discussions on Twitter

Compare VERV with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VERV Verve Therapeutics Inc	11.12	984.22M	20.65M	-192.65M	-134.39M	-2.59
VRTX Vertex Pharmaceuticals Inc	476.38	119.21B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	572.62	59.16B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	327.11	40.57B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	572.47	34.02B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	294.93	29.19B	3.81B	-644.79M	-669.77M	-6.24

Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-15-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Apr-08-24	Initiated	H.C. Wainwright	Buy
Apr-13-23	Initiated	Canaccord Genuity	Buy
Feb-01-23	Initiated	Cantor Fitzgerald	Neutral
Dec-15-22	Initiated	Goldman	Sell
Oct-06-22	Initiated	Credit Suisse	Neutral
Aug-25-22	Upgrade	Stifel	Hold → Buy
Jun-17-22	Initiated	BMO Capital Markets	Outperform
Feb-18-22	Initiated	RBC Capital Mkts	Outperform
Sep-24-21	Initiated	Stifel	Hold
Jul-12-21	Initiated	Guggenheim	Buy
Jul-12-21	Initiated	JP Morgan	Neutral
Jul-12-21	Initiated	Jefferies	Buy
Jul-12-21	Initiated	William Blair	Outperform

View All

Verve Therapeutics Inc Stock (VERV) Latest News

11:01 AM

Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition - Yahoo Finance

11:01 AM

Jul 22, 2025

What drives Verve Therapeutics Inc. stock priceBreakthrough wealth creation - Autocar Professional

Jul 22, 2025

Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B - MSN

Jul 22, 2025

Eli Lilly, Verve Therapeutics receive early termination from US FTC - MLex

Jul 22, 2025

What analysts say about Verve Therapeutics Inc. stockHigh-yield investments - jammulinksnews.com

Jul 22, 2025

Is Verve Therapeutics Inc. a good long term investmentPhenomenal trading returns - jammulinksnews.com

Jul 22, 2025

(VERV) Trading Advice - news.stocktradersdaily.com

Jul 22, 2025

Jul 21, 2025

Verve Therapeutics Inc. Stock Analysis and ForecastConsistent triple-digit returns - Autocar Professional

Jul 21, 2025

3 Bullish Biotech Stocks With Explosive Growth Trends - MarketBeat

Jul 21, 2025

Jul 19, 2025

Eli Lilly acquires Verve Therapeutics in $1.3 billion deal, validating gene editing for heart disease - drugdiscoverytrends.com

Jul 19, 2025

Is Verve Therapeutics Inc. stock a good hedge against inflationFree AI-Driven Trading Strategies - beatles.ru

Jul 19, 2025

Jul 15, 2025

Verve Offers $416K Award To GC Amid Lilly Acquisition - Law360

Jul 15, 2025

Verve Therapeutics grants retention bonuses to CFO and COO amid pending acquisition - Investing.com Canada

Jul 15, 2025

Verve Therapeutics grants retention bonuses to CFO and COO amid pending acquisition By Investing.com - Investing.com South Africa

Jul 15, 2025

Verve Therapeutics Announces Retention Bonus Program for Executives - TipRanks

Jul 15, 2025

Jul 14, 2025

Why Verve Therapeutics Inc. stock attracts strong analyst attentionDaily Trade Opportunity - beatles.ru

Jul 14, 2025

Jul 13, 2025